Artrya (ASX:AYA) said that Mass General Brigham has agreed to participate as a collaborator in the company's SAPPHIRE study, to assess the role of the company's platform, Salix, in detecting coronary artery disease earlier and more effectively, according to a Wednesday filing with the Australian bourse.
The company expects to launch the study in early 2026, the filing said.
Shares of the company fell past 6% in recent Wednesday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.